Dimebon (Medivation/Pfizer) fails pivotal Phase III CONCERT study in Alzheimers Disease and development terminated.

The CONCERT trial is a Phase III trial that evaluated Dimebon (latrepirdine), from Medivation/Pfizer, which was added to ongoing treatment with donepezil HCL tablets in patients with mild-to-moderate Alzheimer�s Disease. Dimebon did not achieve statistically significant results for either of the two co-primary endpoints, the Alzheimer�s Disease Assessment Scale � cognitive subscale (ADAS-cog), which measures cognitive ability, or the Alzheimer�s Disease Cooperative Study � Activities of Daily Living (ADCS-ADL), which measures self care and daily function. Medivation and Pfizer will discontinue development of Dimebon for all indications and will terminate the ongoing open label extension study in Alzheimer�s disease. The companies also announce that they will terminate their collaboration for this drug.